TY  - JOUR
T1  - Treatment of Arthritis with Ulcerative Colitis
AU  - Sulıma, Olena
AU  - Sulyma, Volodymyr
PY  - 2018
DA  - August
JF  - The Eurasia Proceedings of Science Technology Engineering and Mathematics
JO  - EPSTEM
PB  - ISRES Publishing
WT  - DergiPark
SN  - 2602-3199
SP  - 262
EP  - 264
IS  - 2
LA  - en
AB  - Arthritis, or joint inflammation, is the mostcommon complication of ulcerative colitis. Twenty-five percent of people withulcerative colitis suffer from it, and it is often found in young patients. Inaddition to joint pain, arthritis also causes swelling and stiffness (stiffnessin the joint). With ulcerative colitis, arthritis can manifest itself in twodifferent forms: Peripheral arthritis usually affects large joints of the handsand feet, including elbows, wrists, knees and ankles. Pain can"migrate" from one joint to another and last from a few days toseveral weeks. The more intense the inflammatory process in the colon, the morepronounced arthritis. To date, there are no special tests to confirm ulcerativecolitis-associated arthritis. This diagnosis can be made only by eliminatingother causes of pain in the joints. Fortunately, such peripheral arthritisusually does not cause a significant change in the function of the joint.Spondyloarthritis (arthritis of the intervertebral joints) causes pain andstiffness in the lower part of the spine and sacroiliac joints. In youngpeople, these symptoms may appear much earlier than intestinal manifestations.Unlike peripheral arthritis, spondyloarthritis can lead to a significantdeterioration in the function of the spine, as the amount of movement in theintervertebral joints decreases. Spondylitis usually appears at the age ofabout 35-45 years. In most cases, the symptoms of peripheral arthritis decreasewith the disappearance of inflammation in the large intestine. After a courseof drugs such as prednisolone or sulfasalazine, joint pain usually disappears.The use of Infliximab (Remicade ®) for the treatment effectively reducesinflammation and swelling of the joints. Unlike peripheral arthritis,unfortunately, in spondyloarthritis there is no such clear relationship betweenthe disappearance of signs of inflammation in the intestine and thedisappearance of joint symptoms. In such patients, non-steroidalanti-inflammatory drugs (NSAIDs) are used to relieve pain and swelling of thejoints. However, these drugs should be used under the supervision of a doctor,as they can provoke an exacerbation, since they irritate the intestinal mucosa.To prevent a decrease in the volume of movement in the joints it is veryimportant to engage in exercise therapy.
KW  - Arthritis
KW  - Ulcerative colitis
KW  - Treatment
CR  - Brodszky V., Baji P., Balogh O., Péntek M. (2014). Budget impact analysis of biosimilar infliximab (CT-P13)    for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur. J. Health Econ. 15(Suppl. 1), S65–S71. 10.1007/s10198-014-0595-3 [PMC free article][PubMed] [Cross Ref]
Cooksey R., Husain M. J., Brophy S., Davies H., Rahman M. A., Atkinson M. D., et al. . (2015). The cost of Ankylosing Spondylitis in the UK using linked routine and patient-reported survey data. PLoS ONE 10:e0126105. 10.1371/journal.pone.0126105 [PMC free article] [PubMed] [Cross Ref]
Danese S., Gomollon F. (2013). Governing board and operational board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J. Crohns. Colitis 7, 586–589. 10.1016/j.crohns.2013.03.011 [PubMed] [Cross Ref]
Dignass A., Lindsay J. O., Sturm A., Windsor A., Colombel J. F., Allez M., et al. . (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J. Crohns. Colitis 6, 991–1030. 10.1016/j.crohns.2012.09.002 [PubMed][Cross Ref]
Dörner T., Kay J. (2015). Biosimilars in rheumatology: current perspectives and lessons learnt. Nat. Rev. Rheumatol. 11, 713–724. 10.1038/nrrheum.2015.110 [PubMed] [Cross Ref]
Fautrel B., Woronoff-Lemsi M. C., Ethgen M., Fein E., Monnet P., Sibilia J., et al. . (2005). Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFα biological therapy in France. Joint Bone Spine 72, 550–556. 10.1016/j.jbspin.2004.12.009 [PubMed][Cross Ref]
UR  - https://dergipark.org.tr/en/pub/epstem/issue//455948
L1  - https://dergipark.org.tr/en/download/article-file/528329
ER  -